The drugs listed are in alphabetical order. Bendamustine hydrochloride injection: Apotex on Jan. 27 reported the discontinuation of both the 25 mg and 100 mg presentations of bendamustine ...
The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...
Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable ...
Additional studies are needed to evaluate if and to what degree febuxostat displaces other highly protein-bound drugs and its potential long-term effects on hepatic function. Trials that include ...
An alternative XOI, Febuxostat, launched in the US in 2009 with the hope ... At XORTX, we are dedicated to developing medications to improve the quality of life and health of kidney disease patients ...
The goal of treatment is to reduce levels of uric acid in the blood below the 6 mg/dl threshold, but in some cases, current drugs like allopurinol and febuxostat aren’t able to achieve that ...
Current first-line therapies like allopurinol and febuxostat can be very effective ... while others are intolerant to the drugs. Sobi’s filing is based on the DISSOLVE I and II pivotal studies ...
Other medications for gout.In some cases ... Allopurinol (Lopurin, Zyloprim) Febuxostat (Uloric) Probenecid (Probalan) Pegloticase (Krystexxa) Just because you have a flare doesn't mean your ...
Sometimes, they may prescribe a drug such as allopurinol (Zyloprim) or febuxostat (Uloric) to lower your uric acid levels. Your doctor will decide whether it’s safe for you to continue taking ...
Globalpharma, the UAE’s leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, has unveiled ...
Medications commonly used to treat gout include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, corticosteroids, and xanthine oxidase inhibitors (e.g., allopurinol, febuxostat) to lower ...
Febuxostat is a xanthine oxidase inhibitor (XOI ... may enable it to be used at a low enough dose to have potentially less drug-drug interaction issues in patients with gout who receive concurrent ...